Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1993 1
1997 1
2000 1
2003 2
2008 3
2009 6
2010 6
2011 3
2012 3
2013 4
2014 6
2015 3
2016 9
2017 8
2018 10
2019 6
2020 15
2021 12
2022 16
2023 13
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Booster dose vaccination for preventing hepatitis B.
Poorolajal J, Mahmoodi M, Haghdoost A, Majdzadeh R, Nasseri-Moghaddam S, Ghalichi L, Fotouhi A. Poorolajal J, et al. Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008256. doi: 10.1002/14651858.CD008256.pub2. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2016 Jun 07;(6):CD008256. doi: 10.1002/14651858.CD008256.pub3. PMID: 21069704 Updated. Review.
BACKGROUND: Antibodies against hepatitis B surface antigen (HBs) wane over time after vaccination for hepatitis B (HB); hence, the duration of protection provided by the vaccine is still unknown but may be evaluated indirectly by measuring the anamnestic immune resp …
BACKGROUND: Antibodies against hepatitis B surface antigen (HBs) wane over time after vaccination for hepatitis B (HB); hence, …
Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis.
Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Poorolajal J, et al. Vaccine. 2010 Jan 8;28(3):623-31. doi: 10.1016/j.vaccine.2009.10.068. Epub 2009 Nov 1. Vaccine. 2010. PMID: 19887132 Review.
The duration of protection provided by hepatitis B vaccine is still unknown but can be estimated through long-term follow-up studies. ...Randomized clinical trials and prospective cohort studies addressing the long-term protective effect of hepatitis B vaccine were …
The duration of protection provided by hepatitis B vaccine is still unknown but can be estimated through long-term follow-up studies. …
Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
Mahmood I. Mahmood I. Clin Pharmacokinet. 1997 Aug;33(2):91-102. doi: 10.2165/00003088-199733020-00002. Clin Pharmacokinet. 1997. PMID: 9260033 Review.
Selegiline is a selective inhibitor of monoamine oxidase-B (MAO-B) at a dose of 10 mg/day and is given to patients with Parkinson's disease as an adjunct to levodopa therapy. By inhibiting MAO-B, selegiline increases the dopamine levels in the substantia nigr …
Selegiline is a selective inhibitor of monoamine oxidase-B (MAO-B) at a dose of 10 mg/day and is given to patients with Parkin …
Toll-like receptor 2: An important immunomodulatory molecule during Helicobacter pylori infection.
Nemati M, Larussa T, Khorramdelazad H, Mahmoodi M, Jafarzadeh A. Nemati M, et al. Life Sci. 2017 Jun 1;178:17-29. doi: 10.1016/j.lfs.2017.04.006. Epub 2017 Apr 18. Life Sci. 2017. PMID: 28427896 Review.
TLR2 plays a pivotal role in regulation of immune response to H. pylori through activation of NF-kappaB and induction of cytokine expression in epithelial cells, monocytes/macrophages, dendritic cells, neutrophils and B cells. The TLR2-related immune response that is induc …
TLR2 plays a pivotal role in regulation of immune response to H. pylori through activation of NF-kappaB and induction of cytokine expression …
Single High-Sensitivity Point-of-Care Whole-Blood Cardiac Troponin I Measurement to Rule Out Acute Myocardial Infarction at Low Risk.
Apple FS, Smith SW, Greenslade JH, Sandoval Y, Parsonage W, Ranasinghe I, Gaikwad N, Schulz K, Stephensen L, Schmidt CW, Okeson B, Cullen L; SAMIE Investigators. Apple FS, et al. Circulation. 2022 Dec 20;146(25):1918-1929. doi: 10.1161/CIRCULATIONAHA.122.061148. Epub 2022 Oct 31. Circulation. 2022. PMID: 36314160 Free article.
Application of SrFeO(3) perovskite as electrode material for supercapacitor and investigation of Co-doping effect on the B-site.
Ahangari M, Mahmoodi E, Delibaş N, Mostafaei J, Asghari E, Niaei A. Ahangari M, et al. Turk J Chem. 2022 Sep 1;46(5):1723-1732. doi: 10.55730/1300-0527.3475. eCollection 2022. Turk J Chem. 2022. PMID: 37529725 Free PMC article.
From the obtained results, it was found that Co doping with a ratio of 1/1 (Co/Fe) at B site of SrFeO(3) reduced the specific capacitance from 101.687 F g(-1) to 60.912 F g(-1) at a scan rate of 10 mV s(-1). Also, the specific capacitance of SrCoO(3) decreased from 68.639 …
From the obtained results, it was found that Co doping with a ratio of 1/1 (Co/Fe) at B site of SrFeO(3) reduced the specific capacit …
Microtubule stabilizer epothilone B as a motor neuron differentiation agent for human endometrial stem cells.
Mahmoodi N, Ai J, Ebrahimi-Barough S, Hassannejad Z, Hasanzadeh E, Basiri A, Vaccaro AR, Rahimi-Movaghar V. Mahmoodi N, et al. Cell Biol Int. 2020 May;44(5):1168-1183. doi: 10.1002/cbin.11315. Epub 2020 Feb 18. Cell Biol Int. 2020. PMID: 32022385
However, recent studies have revealed that one particular MSA, epothilone B (EpoB), can promote axonal regeneration after traumatic spinal cord injuries (SCI) even in the presence of inhibitor molecules such as neurite outgrowth inhibitor-A (Nogo-A). ...
However, recent studies have revealed that one particular MSA, epothilone B (EpoB), can promote axonal regeneration after traumatic s …
Quality of life in sarcopenia measured with the SarQoL questionnaire: A meta-analysis of individual patient data.
Beaudart C, Tilquin N, Abramowicz P, Baptista F, Peng DJ, de Souza Orlandi F, Drey M, Dzhus M, Fábrega-Cuadros R, Fernandez-Garrido J, Laurindo LF, Gasparik AI, Geerinck A, Emin G, Iacob S, Kilaitė J, Kumar P, Lee SC, Lou VWQ, Mahmoodi M, Matijevic R, Matveeva MV, Merle B, Montero-Errasquín B, Bhattoa HP, Safonova Y, Şimşek H, Topinkova E, Tsekoura M, Erdoğan T, Yoo JI, Yu R, Hiligsmann M, Reginster JY, Bruyère O. Beaudart C, et al. Maturitas. 2024 Feb;180:107902. doi: 10.1016/j.maturitas.2023.107902. Epub 2023 Dec 15. Maturitas. 2024. PMID: 38142467 Free article.
Correlation of Serum Levels of Interleukine-16, CCL27, Tumor Necrosis Factor-related Apoptosis-inducing Ligand, and B-cell Activating Factor with Multiple Sclerosis Severity.
Kouchaki E, Akbari H, Mahmoudi F, Salehi M, Naimi E, Nikoueinejad H. Kouchaki E, et al. Iran J Allergy Asthma Immunol. 2022 Feb 6;21(1):27-34. doi: 10.18502/ijaai.v21i1.8610. Iran J Allergy Asthma Immunol. 2022. PMID: 35524375 Free article.
The pathogenic roles of Interleukine-16 (IL-16), CCL27, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and B-cell activating factor (BAFF) has been shown in some autoimmune and inflammatory diseases. ...
The pathogenic roles of Interleukine-16 (IL-16), CCL27, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and B-cell a …
117 results